Goldman Sachs Group Inc Outlook Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$555 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.22 - $0.66 $1,297 - $3,892	-5,898 Reduced 9.63%	55,334 $21,000
Q3 2023 May 14, 2024	BUY	$0.2 - $1.78 $1,179 - $10,498	5,898 Added 10.66%	61,232 $13,000
Q3 2023 Nov 14, 2023	SELL	$0.2 - $1.78 $14,277 - $127,072	-71,389 Reduced 53.83%	61,232 $13,000
Q2 2023 May 14, 2024	BUY	$1.02 - $1.89 $62,830 - $116,422	61,599 Added 86.73%	132,621 $230,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $62,830 - $116,422	61,599 Added 86.73%	132,621 $230,000

Q1 2023 May 14, 2024	SELL	$1.0 - $1.35 $116,525 - $157,308	-116,525 Reduced 62.13%	71,022 $77,000
Q1 2023 May 11, 2023	SELL	$1.0 - $1.35 $116,525 - $157,308	-116,525 Reduced 62.13%	71,022 $77,000
Q4 2022 May 14, 2024	BUY	$0.87 - $1.33 $80,790 - $123,507	92,863 Added 98.08%	187,547 $202,000
Q4 2022 Feb 13, 2023	BUY	$0.87 - $1.33 $80,790 - $123,507	92,863 Added 98.08%	187,547 $202,000
Q3 2022 May 14, 2024	SELL	$1.02 - $1.26 $10,786 - $13,324	-10,575 Reduced 10.05%	94,684 $115,000
Q3 2022 Nov 10, 2022	SELL	$1.02 - $1.26 $10,786 - $13,324	-10,575 Reduced 10.05%	94,684 $115,000
Q2 2022 May 14, 2024	BUY	$0.91 - $2.01 $45,431 - $100,349	49,925 Added 90.22%	105,259 $107,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $29,904 - $66,052	-32,862 Reduced 23.79%	105,259 $107,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $32,692 - $54,397	26,797 Added 24.07%	138,121 $246,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $50,528 - $88,722	-39,786 Reduced 26.33%	111,324 $152,000
Q3 2021 Nov 10, 2021	BUY	$2.12 - $2.76 $320,353 - $417,063	151,110 New	151,110 $328,000

Others Institutions Holding OTLK

# of Institutions

Shares Held

67.1K

Call Options Held

Put Options Held

View Full List

About Outlook Therapeutics, Inc.

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

More about OTLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account